CoChat

Intraneuronal Aβ immunoreactivity is not a predictor of brain amyloidosis-β or neurofibrillary degeneration

Open access
Wegiel, Jerzy, Kuchna, Izabela, Nowicki, Krzysztof, Frackowiak, Janusz, Mazur-Kolecka, Bozena, Imaki, Humi, Wegiel, Jarek, Mehta, Pankaj D., Silverman, Wayne P., Reisberg, Barry, deLeon, Mony, Wisniewski, Thomas, Pirttilla, Tuula, Frey, Harry, Lehtimäki, Terho, Kivimäki, Tarmo, Visser, Frank E., Kamphorst, Wouter, Potempska, Anna, Bolton, David, Currie, Julia R., Miller, David L. · 2007 · Acta Neuropathologica
Cited by 92

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

Abstract

Amyloid beta (Abeta) immunoreactivity in neurons was examined in brains of 32 control subjects, 31 people with Down syndrome, and 36 patients with sporadic Alzheimer's disease to determine if intraneuronal Abeta immunoreactivity is an early manifestation of Alzheimer-type pathology leading to fibrillar plaque formation and/or neurofibrillary degeneration. The appearance of Abeta immunoreactivity in neurons in infants and stable neuron-type specific Abeta immunoreactivity in a majority of brain structures during late childhood, adulthood, and normal aging does not support this hypothesis. The absence or detection of only traces of reaction with antibodies against 4-13 aa and 8-17 aa of Abeta in neurons indicated that intraneuronal Abeta was mainly a product of alpha- and gamma-secretases (Abeta(17-40/42)). The presence of N-terminally truncated Abeta(17-40) and Abeta(17-42) in the control brains was confirmed by Western blotting and the identity of Abeta(17-40) was confirmed by mass spectrometry. The prevalence of products of alpha- and gamma -secretases in neurons and beta- and gamma-secretases in plaques argues against major contribution of Abeta-immunopositive material detected in neuronal soma to amyloid deposit in plaques. The strongest intraneuronal Abeta(17-42) immunoreactivity was observed in structures with low susceptibility to fibrillar Abeta deposition, neurofibrillary degeneration, and neuronal loss compared to areas more vulnerable to Alzheimer-type pathology. These observations indicate that the intraneuronal Abeta immunoreactivity detected in this study is not a predictor of brain amyloidosis or neurofibrillary degeneration. The constant level of Abeta immunoreactivity in structures free from neuronal pathology during essentially the entire life span suggests that intraneuronal amino-terminally truncated Abeta represents a product of normal neuronal metabolism.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s00401-006-0191-4

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 46

  1. Allsop D, Haga S, Bruton C, Ishii T, Roberts GW (1990) Neurofibrillary tangles in some cases of dementia pugilistica share antigens with amyloid beta protein of Alzheimer’s disease. Am J Pathol 136:255–260
  2. Bahr BA, Hoffman KB, Yang AJ, Hess US, Glabe CG, Lynch G (1998) Amyloid β-protein is internalized selectively by hippocampal field CA1 and neurons to accumulate amyloidogenic carboxyterminal fragments of the amyloid precursor protein. J Comp Neurol 397:139–147 · DOI · Paper page
  3. Bancher C, Grundke-Iqbal I, Kim KS, Wisniewski HM (1989) Immunoreactivity of neuronal lipofuscin, with monoclonal antibodies to the amyloid β-protein. Neurobiol Aging 10:125–132 · DOI
  4. Braak H, Braak E (1995) Staging of Alzheimer’s disease-related neurofibrillary changes. Neurobiol Aging 16:271–284 · DOI · Paper page
  5. Cook DG, Forman MS, Sung JC, Leight S, Kolson DL, Iwatsubo T, Lee VM, Doms RW (1997) Alzheimer’s Aβ (1–42) is generated in the endoplasmic reticulum/intermediate compartment of NT2N cells. Nat Med 3:1021–1023 · DOI · Paper page
  6. Frackowiak J, Zoltowska A, Wisniewski H (1994) Non-fibrillar β-amyloid protein is associated with smooth muscle cells of vessel wlls in Alzheimer disease. J Neuropathol Exp Neurol 53:637–645 · DOI · Paper page
  7. Frackowiak J, Miller DL, Potempska A, Sukontasup T, Mazur-Kolecka B (2003) Secretion and accumulation of Aβ by brain vascular smooth muscle cells from AβPP-Swedish transgenic mice. J Neuropathol Exp Neurol 62:685–696 · DOI · Paper page
  8. Frackowiak J, Sukontasup T, Potempska A, Mazur-Kolecka B (2004) Lysosomal deposition of Aβ in cultures of brain vascular smooth muscle cells is enhanced by iron. Brain Res 1002:67–75 · DOI
  9. Goedert M, Spillantini M, Jakes R, Rutherford D, Crowther R (1989) Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer’s disease. Neuron 3:519–526 · DOI · Paper page
  10. Guiroy DC, Mellini M, Miyazaki M, Hilbich C, Safar J, Garruto RM, Yanagihara R, Beyreuther K, Gajdusek DC (1993) Neurofibrillary tangles of Guamanian amyotrophic lateral sclerosis, parkinsonism dementia, and neuropathologically normal Guamanians contain a 4–4.5 kDa protein which is immunorective to anti-amyloid beta/A4 protein antibodies. Acta Neuropathol 86:265–274 · doi:10.1007/bf00304141
  11. Haass C, Hung AY, Schlossmacher MG, Teplow DB, Selkoe DJ (1993) β-amyloid peptide and 3 kDa fragment are derived by distinct cellular mechanisms. J Biol Chem 268:3021–3024 · DOI · Paper page
  12. Hartmann T, Bieger SC, Bruhl B, Tienari PJ, Ida N, Allsop D, Roberts GW, Masters CL, Dotti CG, Unsicker K, Beyreuther K (1997) Distinct sites of intracellular production for Alzheimer’s disease Aβ40/42 amyloid peptides. Nat Med 3:1016–1020 · DOI · Paper page
  13. Hyman BT, Van Hoesen GW, Beyreuther K, Masters CL (1989) A4 amyloid protein immunoreactivity is present in Alzheimer’s disease neurofibrillary tangles. Neurosci Lett 101:352–355 · DOI
  14. Ito H, Hirano A, Yen S-H, Katao S (1991) Demonstration of β amyloid protein containing neurofibrillary tangles in parkinsonism-dementia complex of Guam. Neuropathol Appl Neurobiol 17:365–373 · DOI
  15. Iqbal K, Braak H, Braak E, Grundke-Iqbal I (1993) Silver labeling of Alzheimer neurofibrillary changes and brain β-amyloid. J Histotech 16:335–342 · DOI · Paper page
  16. Kim KS, Miller DL, Sapienza VJ, Chen CMJ, Bai C, Grundke-Iqbal I, Currie J, Wisniewski HM (1988) Neurosci Res Commun 2:121–130
  17. Kim KS, Wen GY, Bancher C, Chen CMJ, Sapienza VJ, Hong H, Wisniewski HM (1990) Detection, quantitation of amyloid β-peptide with 2 monoclonal antibodies. Neurosci Res Comm 7:113–122
  18. Kitamoto T, Ogomori K, Tateishi J, Prusiner S (1987) Methods in laboratory investigation. Formic acid pretreatment enhances immunostaining of cerebral and systemic amyloids. Lab Invest 57:230–236
  19. Kuchna I, Wegiel J, Tarnawski M, Badmaev E, Kozlowski P, Pirttila T, Kivimaki T, Lehtimaki T, Visser F, Devenny D, Silverman W (2001) Alzheimer type pathology in the memory system of people with Down syndrome. J Neuropathol Exp Neurol 60:545
  20. Masters CL, Multhaup G, Simms G, Pottgiesser J, Martins RN, Beyreuther K (1985) Neuronal origin of a cerebral amyloid: neurofibrillary tangles of Alzheimer’s disease contain the same protein as the amyloid plaque cores and blood vessels. EMBO J 4:2757–2763 · DOI · Paper page
  21. McLean CA, Cherny RA, Fraser FW, Fuller SJ, Smith MJ, Beyreuther K, Bush AI, Masters CL (1999) Soluble pool of Aβ amyloid as a determinant of severity of neurodegeneration in Alzheimer’s disease. Ann Neurol 46:860–866 · doi:10.1002/1531-8249(199912)46:6<860::aid-ana8>3.0.co;2-m
  22. Miller DL, Currie JR, Mehta PD, Potempska A, Hwang Yu-Wen, Wegiel J (2003) Humoral immune response to fibrillar β-amyloid peptide. Biochemistry 42:11682–11692 · DOI
  23. Miller DL, Potempska A, Mehta PD (2007) Humoral immune responses to peptides derived from the β-amyloid peptide C-terminal sequence. Amyloid (in press) · DOI
  24. Murphy GM, Forno LS, Higgins L, Scardina JM, Eng LF, Cordell B (1994) Development of monoclonal antibody specific for the COOH-terminal of Aβ-amyloid 1–42 and its immunohistochemical reactivity in Alzheimer’s disease and related disorders. Am J Pathol 144:1082–1088
  25. Payan IL, Chou S-J, Fisher GH, Man EH, Emory C, Frey WH (1992) Altered aspartate in Alzheimer neurofibrillary tangles. Neurochem Res 17:187–191 · DOI
  26. Perry G, Cras P, Siedlak SL, Tabaton M, Kawai M (1992) β protein immunoreactivity is found in the majority of neurofibrillary tangles of Alzheimer’s disease. Am J Pathol 140:283–290
  27. Pike CJ, Overman MJ, Cotman CW (1995) Amino-terminal deletions enhance aggregation of β-amyloid peptides in vitro. J Biol Chem 270:23895–23898 · DOI · Paper page
  28. Potempska A, Mack K, Mehta P, Kim KS, Miller DL (1999) Quantification of sub-femtomole amount of Alzheimer amyloid β peptides. Amyloid 6:14–21 · DOI · Paper page
  29. Reisberg B, Ferris SH, DeLeon MJ, Crook T (1982) The global deterioration scale for the assessment of promary degenerative dementia. Am J Psychol 139:1136–1139 · DOI · Paper page
  30. Reisberg B (1988) Functional assessment staging (FAST). Psychopharmacol Bull 24:653–659
  31. Rosenblum WI (1999) The presence, origin, and significance of Aβ peptide in the cell bodies of neurons. J Neuropathol Exp Neurol 58:575–581 · DOI
  32. Schwab C, Akiyama H, McGeer EG, McGeer PL (1998) Extracellular neurofibrillary tangles are immunopositive for the 40 carboxy-terminal sequence of β-amyloid protein. J Neuropathol Exp Neurol 57:1131–1137 · DOI
  33. Schweers O, Schonbrunn-Hanebeck E, Marx A, Mandelkow E (1994) Structural studies of tau protein and Alzheimer paired helical filaments show no evidence for beta structure. J Biol Chem 269:24290–24297 · DOI · Paper page
  34. Sergeant N, Bombois S, Ghestem A, Drobecq H, Kostanjevecki V, Missiaen C, Wattez A, David J-P, Vanmechelen E, Sergheraert C, Delacourte A (2003) Truncated beta-amyloid peptide species in pre-clinical Alzheimer’s disease as new targets for the vaccination approach. J Neurochem 85:1581–1591 · DOI · Paper page
  35. Shapira R, Austin GE, Mirra SS (1988) Neuritic plaque amyloid is highly racemized. J Neurochem 50:69–74 · DOI · Paper page
  36. Sokol DK, Chen D, Farlow MR, Dunn DW, Maloney B, Zimmer JA, Lahiri DK (2006) High levels of Alzheimer beta- amyloid precursor protein (APP) in children with severely autistic behavior and aggression. J Child Neurol 21:444–449 · DOI · Paper page
  37. Stern RA, Otvos L Jr, Trojanowski JQ, Lee VM (1989) Monoclonal antibodies to a synthetic peptide homologous with the first 28 amino acids of Alzheimer’s diease beta-protein recognize amyloid and diverse glial and neuronal cell types in the central nervous system. Am J Pathol 134:973–978
  38. Tabaton M, Cammarata S, Mancardi G, Manetto V, Autilio-Gambetti L, Perry G, Gambetti P (1991) Ultrastructural localization of β-amyloid, tau and ubiquitin epitopes in extracellular neurofibrillary tangles. Proc Natl Acad Sci USA 88:2098–2102 · DOI · Paper page
  39. Takahashi RH, Nam EE, Edgar M, Gouras GK (2002) Alzheimer β-amyloid peptides: normal and abnormal localization. Histol Histopathol 17:239–246
  40. Wang R, Sweeney D, Gandy SE, Sisodia S (1996) The profile of soluble amyloid β protein in cultured media. J Biol Chem 271:31894–31902 · DOI · Paper page
  41. Wegiel J, Wisniewski HM, Morys J, Tarnawski M, Kuchna I, Dziewiatkowski J, Pirttilä T, Krivimäki T, Lehtimäki T, Lach B (1999) Neuronal loss and amyloid-β removal in the amygdala of people with Down syndrome. Neurobiol Aging 20:259–269 · DOI
  42. Wegiel J, Kuchna I, Miller D, Mehta P, Wegiel J, Wisniewski T, Reisberg B, Silverman W (2002) Intraneuronal accumulation of N-terminally truncated amyloid beta. J Neuropathol Exp Neurol 61:483
  43. Wilson CA, Doms RW, Lee VM-Y (1999) Intracellular APP processing and Aβ production in Alzheimer disease. J Neuropathol Exp Neurol 58:787–794 · DOI · Paper page
  44. Wisniewski KE, Maslinska D, Kitaguchi T, Kim KS, Goebel HH, Haltia M (1990) Topographic heterogeneity of amyloid β-protein epitopes in brains with various forms of neuronal lipofuscinoses suggesting defective processing of amyloid precursor protein. Acta Neuropathol 80:26–34 · DOI
  45. Xu H, Sweeney D, Wang R, Thinakaran G, Lo ACY, Sisodia SS, Greengard P, Gandy S (1997) Generation of Alzheimer’s β-amyloid protein in the trans-Golgi in the apparent absence of vesicle formation. Proc Natl Acad Sci USA 94:3748–3752 · DOI · Paper page
  46. Yamaguchi H, Nakazato Y, Shoji M, Okamoto K, Ihara Y, Morimatsu M, Hirai S (1991) Secondary deposition of beta amyloid within extracellular neurofibrillary tangles in Alzheimer-type dementia. Am J Pathol 138:699–705

Cited by

See all 92

Metadata

Authors
Wegiel, J., Kuchna, I., Nowicki, K., Frackowiak, J., Mazur-Kolecka, B., Imaki, H., Wegiel, J., Mehta, P. D., Silverman, W. P., Reisberg, B., deLeon, M., Wisniewski, T., Pirttilla, T., Frey, H., Lehtimäki, T., Kivimäki, T., Visser, F. E., Kamphorst, W., Potempska, A., Bolton, D., Currie, J. R., & Miller, D. L.
Venue
Acta Neuropathologica
Published
2007-01-20
Volume
113
Issue
4
Pages
389-402
ISSN
  • 0001-6322 (ISSN-L)
  • 1432-0533
OpenAlex
W2127714088
Cited by
92
References
22
FWCI
6.72
Type
journal article
Language
en
Open access
hybrid
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.